The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per month without leaving the platform.
Feature|Podcasts|March 11, 2025
The Misinformation Maze: Navigating Public Health in the Digital Age
Author(s)Miranda Schmalfuhs
Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Advertisement
In this episode of the Pharmaceutical Executive podcast, Jennifer Butler, chief commercial officer of Pleio, discusses:
- The threat of misinformation to public health and how emotional appeal plays a part.
- Where patients are turning for trustworthy health information.
- Strategies that can be used to verify information.
- Pharma's role in helping to ensure patients have access to health insights they can trust.
- Why the industry is turning to peer-to-patient platforms, trusted patient communities, and pharmacies to educate patients.
- What kind of role regulatory agencies should play in the battle against misinformation.
- and more!
Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peet-to-patient strategies to educate patients, and more.
Advertisement
Related to this article
Dr. Jay Lalezari of CytoDyn explains why Leronlimab’s circulating tumor DNA results in colorectal cancer represent a unique, mechanism-specific proof of concept rather than a broader template.
PhRMA's Scott LaGanga discusses the expanding influence of state policymaking on drug pricing, PBM reform, and efforts to translate policy changes into lower out-of-pocket costs for patients.
Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its research collaboration with Korro Bio, and the FDA grants accelerated approval to Johnson & Johnson’s Rybrevant Faspro in head and neck cancer.
ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics as Egetis separately sells its priority review voucher for $190 million, Novartis exits its BrainTransporter deal with BioArctic 14 months after signing, and Ignite Proteomics’ Dr. Brian Corgiat on improving how tumors are tested after recurrence.
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
Boehringer Ingelheim licenses six preclinical oncology programs from Sino Biopharmaceutical in a deal worth up to $7 billion, while Nxera Pharma licenses its EP4 agonist program for inflammatory bowel disease to AbbVie for up to $1.37 billion.
Dr. Jay Lalezari, CEO and CMO of CytoDyn, discusses how Leronlimab’s unique CCR5-blocking mechanism has carried it from HIV, to Covid-19, to a promising, one-of-a-kind proof of concept in colorectal cancer.
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro
2
Hims & Hers Partners with Eli Lilly to Sell Obesity Medicines
3
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
4
The US Drug-Pricing Reset: Competing on Net Value
5